FDA approves tucatinib (Tukysa) for metastatic Her2-positive breast cancer
https://www.facingourrisk.org/XRAY/fda-approval-tucatinib-metastatic-her2-positive-breast-cancer
Full article: https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-drug-under-international-collaboration-treatment-option-patients-her2
The FDA has approved the use of tucatinib (Tukysa) in combination with chemotherapy as a treatment for people with metastatic Her2-positive breast cancer. This approval includes treatment of people whose breast cancer has spread to the brain. (4/29/20)
Questions To Ask Your Health Care Provider
- Is Tuksya a treatment option for my type of breast cancer?
- If Tukysa is not an option for me right now, might it be an option in the future?
- What side effects might I experience with this treatment?
- If I have serious side effects, will I need to stop treatment?
- Are any other agents available to treat my cancer?
Open Clinical Trials
The following studies look at treatment for people with metastatic HER2-positive breast cancer:
- NCT05458674: Tucatinib+Trastuzumab+Eribulin in HER2+ MBC. This study evaluates the safety and efficacy of combining the drugs tucatinib, trastuzumab and eribulin in patients with unresectable metastatic HER2-positive breast cancer after prior treatment with a taxane, trastuzumab and T-DM1.
- NCT06100874: A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN). This study evaluates the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta or trastuzumab biosimilar) in metastatic HER2+ breast cancer.
- NCT06435429: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer. This study evaluates the safety and effectiveness of zanidatamab combined with chemotherapy compared to trastuzumab (Herceptin) combined with chemotherapy to treat participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous T-DXd treatment.
- NCT05378464: Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer. This study tests the safety of Adoptive T-Cell therapy following the Dendritic Cell (DC1) vaccine given in combination with pepinemab added to standard-of-care therapy trastuzumab for people with HER2-positive breast cancer.
- NCT05894239: A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer. This study looks at the safety and effectiveness of inavolisib combined with Phesgo (pertuzumab, trastuzumab and rHuPH20 injection) compared with a placebo combined with Phesgo for maintenance therapy after induction therapy for participants with previously untreated HER2-positive advanced breast cancer.
Other clinical trials for people with breast cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.